Zimmer Biomet Holdings EMEA — Operating Income decreased by 8.4% to $152.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.1%, from $150.50M to $152.20M. Over 4 years (FY 2021 to FY 2025), EMEA — Operating Income shows an upward trend with a 10.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher operating income indicates strong regional profitability and effective cost management.
The profit or loss generated by the EMEA segment after deducting cost of goods sold and operating expenses from total re...
The primary metric for comparing regional performance and profitability across the medical device industry.
zbh_segment_emea_operating_income_loss| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $91.90M | $86.90M | $144.90M | $104.90M | $104.30M | $85.80M | $115.10M | $149.50M | $132.00M | $101.00M | $162.50M | $154.80M | $151.60M | $123.80M | $164.10M | $150.50M | $158.50M | $121.80M | $166.10M | $152.20M |
| QoQ Change | — | -5.4% | +66.7% | -27.6% | -0.6% | -17.7% | +34.1% | +29.9% | -11.7% | -23.5% | +60.9% | -4.7% | -2.1% | -18.3% | +32.6% | -8.3% | +5.3% | -23.2% | +36.4% | -8.4% |
| YoY Change | — | — | — | — | +13.5% | -1.3% | -20.6% | +42.5% | +26.6% | +17.7% | +41.2% | +3.5% | +14.8% | +22.6% | +1.0% | -2.8% | +4.6% | -1.6% | +1.2% | +1.1% |